RCAN1 (Regulator of Calcineurin 1), also known as DSCR1 (Down Syndrome Critical Region 1), is a critical endogenous regulator of the calcineurin-NFAT signaling pathway. RCAN1 is highly expressed in the brain and is particularly relevant to neurodegenerative diseases due to its role in tau phosphorylation, synaptic plasticity, and cellular stress responses. The gene is located on chromosome 21, explaining its overexpression in Down syndrome and its contribution to early-onset Alzheimer's disease in individuals with trisomy 21. [1]
RCAN1 PROTEIN is an endogenous inhibitor of calcineurin signaling that plays a dual role in neurodegeneration - protecting neurons from excessive calcineurin activity while potentially contributing to pathology when dysregulated. RCAN1 is implicated in Alzheimer's disease, Parkinson's disease, Down syndrome-associated neurodegeneration, and stroke. [2]
| Property | Value | [3]
|----------|-------| [4]
| Gene | RCAN1 (DSCR1) | [5]
| UniProt ID | P53805 | [6]
| Molecular Weight | 28 kDa | [7]
| Protein Class | Calcineurin inhibitor | [8]
| Subcellular Localization | Cytoplasm, nucleus |
| Brain Expression | High in cortex, hippocampus, cerebellum |
| Chromosome | 21q22.12 |
RCAN1 has several structural features:
The protein exists in multiple isoforms generated by alternative splicing, with RCAN1.1 and RCAN1.4 being the major brain isoforms.
RCAN1's primary function is to regulate calcineurin activity:
In neurons, RCAN1 regulates:
RCAN1 is critically involved in AD pathogenesis:
The RCAN1-calcineurin axis offers therapeutic opportunities:
RCAN1 as a biomarker:
| Protein | Interaction Type | Function |
|---|---|---|
| Calcineurin (PPP3CA/PPP3CB) | Direct binding | Inhibition |
| NFAT1-4 | Indirect | Regulation |
| GSK3β | Phosphorylation | Tau phosphorylation |
| 14-3-3 proteins | Binding | Stability |
| Hsp90 | Chaperone complex | Folding |
The study of Rcan1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
RCAN1 overexpression accelerates amyloid pathology in a mouse model of Alzheimer's disease. 2012. ↩︎
The calcineurin-NFAT signaling system in Alzheimer's disease. 2015. ↩︎
RCAN1.1 is a calcium-dependent calcineurin regulator in Alzheimer's disease. 2007. ↩︎
Chromosome 21 gene dysregulation in Down syndrome brains. 2007. ↩︎
Calcineurin inhibitory therapy for Alzheimer's disease. 2014. ↩︎